Russell Investments Group Ltd. Acquires 25,671 Shares of Jazz Pharmaceuticals PLC $JAZZ

Russell Investments Group Ltd. raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 50.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 76,421 shares of the specialty pharmaceutical company’s stock after buying an additional 25,671 shares during the quarter. Russell Investments Group Ltd. owned 0.12% of Jazz Pharmaceuticals worth $17,696,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in JAZZ. USA Financial Formulas acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter worth $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC acquired a new position in Jazz Pharmaceuticals during the 2nd quarter valued at $47,000. Westpac Banking Corp acquired a new position in Jazz Pharmaceuticals during the 1st quarter valued at $51,000. Finally, Elevation Wealth Partners LLC boosted its holdings in Jazz Pharmaceuticals by 156.4% in the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 158 shares during the period. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on JAZZ shares. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. UBS Group increased their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Citigroup initiated coverage on Jazz Pharmaceuticals in a research note on Wednesday, September 30th. They set a “buy” rating and a $325.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

Read Our Latest Analysis on JAZZ

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,413 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,506,616.32. This trade represents a 17.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Renée Galá sold 2,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total transaction of $486,060.00. Following the completion of the sale, the chief executive officer owned 143,394 shares in the company, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $247.77 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $156.95 and a 52 week high of $266.38. The stock has a market capitalization of $15.90 billion, a PE ratio of 21.34, a PEG ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. The stock’s fifty day moving average is $229.13 and its 200-day moving average is $220.79.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. Jazz Pharmaceuticals’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $8.13 earnings per share. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 11.18 EPS for the current fiscal year.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Featured Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.